{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:37:51Z","timestamp":1740141471274,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The liver is central to the elimination of many drugs from the body involving multiple processes and understanding of these processes is important to quantitively assess hepatic clearance of drugs. The synthetic STING (STimulator of INterferon Genes protein) agonist is a new class of drugs currently being evaluated in clinical trials as a potential anticancer therapy. In this study, we used ML00960317 (synthetic STING agonist) to investigate the hepatobiliary disposition of this novel molecular entity. A bile-duct cannulated (BDC) rat study indicated that biliary excretion is the major route of elimination for ML00960317 (84% of parent dose in bile). The human biliary clearance using <jats:italic>in vitro<\/jats:italic> sandwich cultured human hepatocyte model predicted significant biliary excretion of ML00960317 (biliary excretion index (BEI) of 47%). Moreover, the transport studies using transporter expressing cell lines, hepatocytes, and membrane vesicles indicated that ML00960317 is a robust substrate of OATP1B1, OATP1B3, and MRP2. Using relative expression factor approach, the combined contribution of OATP1B1 (fraction transported (<jats:italic>f<\/jats:italic><jats:sub>t<\/jats:sub>) = 0.62) and OATP1B3 (<jats:italic>f<\/jats:italic><jats:sub>t<\/jats:sub> = 0.31) was found to be 93% of the active uptake clearance of ML00960317 into the liver. Furthermore, OATP1B1 and OATP1B3-mediated uptake of ML00960317 was inhibited by rifampicin with IC<jats:sub>50<\/jats:sub> of 6.5 and 2.3 \u03bcM, respectively indicating an <jats:italic>in vivo<\/jats:italic> DDI risk (R value of 1.5 and 2.5 for OATP1B1 and OATP1B3, respectively). These results highlighted an important role of OATP1B1, OATP1B3, and MRP2 in the hepatobiliary disposition of ML00960317. These pathways may act as rate-determining steps in the hepatic clearance of ML00960317 thus presenting clinical DDI risk.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1208\/s12248-022-00745-7","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T18:08:40Z","timestamp":1663610920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sinusoidal Organic Anion-Transporting Polypeptide 1B1\/1B3 and Bile Canalicular Multidrug Resistance-Associated Protein 2 Play an Essential Role in the Hepatobiliary Disposition of a Synthetic Cyclic Dinucleotide (STING Agonist)"],"prefix":"10.1208","volume":"24","author":[{"given":"Philip","family":"Sandoval","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei-Ching","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapan K.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy Q.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-9011","authenticated-orcid":false,"given":"Paresh P.","family":"Chothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"745_CR1","doi-asserted-by":"publisher","unstructured":"Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23 Suppl 8:viii6-9. https:\/\/doi.org\/10.1093\/annonc\/mds256.","DOI":"10.1093\/annonc\/mds256"},{"issue":"7","key":"745_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1073\/pnas.1621363114","volume":"114","author":"H Wang","year":"2017","unstructured":"Wang H, Hu S, Chen X, Shi H, Chen C, Sun L, et al. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc Natl Acad Sci USA. 2017;114(7):1637\u201342. https:\/\/doi.org\/10.1073\/pnas.1621363114.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7","key":"745_CR3","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018\u201330. https:\/\/doi.org\/10.1016\/j.celrep.2015.04.031.","journal-title":"Cell Rep."},{"issue":"4","key":"745_CR4","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1128\/MCB.01430-12","volume":"33","author":"A Apelbaum","year":"2013","unstructured":"Apelbaum A, Yarden G, Warszawski S, Harari D, Schreiber G. Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol Cell Biol. 2013;33(4):800\u201314. https:\/\/doi.org\/10.1128\/MCB.01430-12.","journal-title":"Mol Cell Biol."},{"issue":"10","key":"745_CR5","doi-asserted-by":"publisher","first-page":"6902","DOI":"10.1021\/acs.jmedchem.1c00374","volume":"64","author":"S Vyskocil","year":"2021","unstructured":"Vyskocil S, Cardin D, Ciavarri J, Conlon J, Cullis C, England D, et al. Identification of novel carbocyclic pyrimidine cyclic dinucleotide STING agonists for antitumor immunotherapy using systemic intravenous route. J Med Chem. 2021;64(10):6902\u201323. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00374.","journal-title":"J Med Chem."},{"issue":"7774","key":"745_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-019-1553-0","volume":"573","author":"RD Luteijn","year":"2019","unstructured":"Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, et al. SLC19A1 transports immunoreactive cyclic dinucleotides. Nature. 2019;573(7774):434\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1553-0.","journal-title":"Nature."},{"issue":"3","key":"745_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/dmd.120.000125","volume":"49","author":"R Jiang","year":"2021","unstructured":"Jiang R, Hart A, Burgess L, Kim DS, Lai WG, Dixit V. Prediction of transporter-mediated drug-drug interactions and phenotyping of hepatobiliary transporters involved in the clearance of E7766, a novel macrocycle-bridged dinucleotide. Drug Metab Dispos. 2021;49(3):265\u201375. https:\/\/doi.org\/10.1124\/dmd.120.000125.","journal-title":"Drug Metab Dispos."},{"issue":"12","key":"745_CR8","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","volume":"32","author":"MV Varma","year":"2015","unstructured":"Varma MV, Steyn SJ, Allerton C, El-Kattan AF. Predicting clearance mechanism in drug discovery: Extended Clearance Classification System (ECCS). Pharm Res. 2015;32(12):3785\u2013802. https:\/\/doi.org\/10.1007\/s11095-015-1749-4.","journal-title":"Pharm Res."},{"issue":"4","key":"745_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/clpt.2011.142","volume":"90","author":"K Maeda","year":"2011","unstructured":"Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther. 2011;90(4):575\u201381. https:\/\/doi.org\/10.1038\/clpt.2011.142.","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"745_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1124\/dmd.109.030254","volume":"38","author":"T Watanabe","year":"2010","unstructured":"Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos. 2010;38(2):215\u201322. https:\/\/doi.org\/10.1124\/dmd.109.030254.","journal-title":"Drug Metab Dispos."},{"issue":"2","key":"745_CR11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/jpet.118.252049","volume":"367","author":"E Kimoto","year":"2018","unstructured":"Kimoto E, Mathialagan S, Tylaska L, Niosi M, Lin J, Carlo AA, et al. Organic anion transporter 2-mediated hepatic uptake contributes to the clearance of high-permeability-low-molecular-weight acid and zwitterion drugs: evaluation using 25 drugs. J Pharmacol Exp Ther. 2018;367(2):322\u201334. https:\/\/doi.org\/10.1124\/jpet.118.252049.","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"745_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1872312810666160411144358","volume":"10","author":"PW Fan","year":"2016","unstructured":"Fan PW, Chen JZ, Allan Jaochico M, La H, Liu N, Mulder T, et al. Rate-determining and rate-limiting steps in the clearance and excretion of a potent and selective p21-activated kinase inhibitor: a case study of rapid hepatic uptake and slow elimination in rat. Drug Metab Lett. 2016;10(2):91\u2013100. https:\/\/doi.org\/10.2174\/1872312810666160411144358.","journal-title":"Drug Metab Lett."},{"key":"745_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fphar.2016.00242","volume":"7","author":"LL Kong","year":"2016","unstructured":"Kong LL, Shen GL, Wang ZY, Zhuang XM, Xiao WB, Yuan M, et al. Inhibition of P-glycoprotein and multidrug resistance-associated protein 2 regulates the hepatobiliary excretion and plasma exposure of thienorphine and its glucuronide conjugate. Front Pharmacol. 2016;7:242. https:\/\/doi.org\/10.3389\/fphar.2016.00242.","journal-title":"Front Pharmacol."},{"issue":"5","key":"745_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1124\/dmd.117.078816","volume":"46","author":"A Futatsugi","year":"2018","unstructured":"Futatsugi A, Toshimoto K, Yoshikado T, Sugiyama Y, Kato Y. Evaluation of alteration in hepatic and intestinal bcrp function in vivo from ABCG2 c.421C>A polymorphism based on PBPK analysis of rosuvastatin. Drug Metab Dispos. 2018;46(5):749\u201357. https:\/\/doi.org\/10.1124\/dmd.117.078816.","journal-title":"Drug Metab Dispos."},{"issue":"1","key":"745_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1124\/dmd.107.017319","volume":"36","author":"X Tian","year":"2008","unstructured":"Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, et al. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos. 2008;36(1):61\u20134. https:\/\/doi.org\/10.1124\/dmd.107.017319.","journal-title":"Drug Metab Dispos."},{"issue":"8","key":"745_CR16","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s11095-017-2168-5","volume":"34","author":"T Yoshikado","year":"2017","unstructured":"Yoshikado T, Maeda K, Furihata S, Terashima H, Nakayama T, Ishigame K, et al. A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions. Pharm Res. 2017;34(8):1570\u201383. https:\/\/doi.org\/10.1007\/s11095-017-2168-5.","journal-title":"Pharm Res."},{"issue":"4","key":"745_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1742-7843.2010.00581.x","volume":"107","author":"A Kalliokoski","year":"2010","unstructured":"Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol. 2010;107(4):775\u201381. https:\/\/doi.org\/10.1111\/j.1742-7843.2010.00581.x.","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"6","key":"745_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clpt.2005.01.018","volume":"77","author":"M Niemi","year":"2005","unstructured":"Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005;77(6):468\u201378. https:\/\/doi.org\/10.1016\/j.clpt.2005.01.018.","journal-title":"Clin Pharmacol Ther."},{"issue":"1-2","key":"745_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cca.2009.04.003","volume":"405","author":"YJ He","year":"2009","unstructured":"He YJ, Zhang W, Chen Y, Guo D, Tu JH, Xu LY, et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009;405(1-2):49\u201352. https:\/\/doi.org\/10.1016\/j.cca.2009.04.003.","journal-title":"Clin Chim Acta."},{"issue":"6","key":"745_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","volume":"82","author":"MK Pasanen","year":"2007","unstructured":"Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82(6):726\u201333. https:\/\/doi.org\/10.1038\/sj.clpt.6100220.","journal-title":"Clin Pharmacol Ther."},{"key":"745_CR21","doi-asserted-by":"publisher","unstructured":"Sandoval P, Chuang BC, Cohen L, Yoneyama T, Pusalkar S, Yucha RW, et al. Sinusoidal uptake determines the hepatic clearance of pevonedistat (TAK-924) as explained by extended clearance model. Drug Metab Dispos. 2022. https:\/\/doi.org\/10.1124\/dmd.122.000836.","DOI":"10.1124\/dmd.122.000836"},{"issue":"4","key":"745_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1124\/dmd.120.000057","volume":"49","author":"PP Chothe","year":"2021","unstructured":"Chothe PP, Pemberton R, Hariparsad N. Function and expression of bile salt export pump in suspension human hepatocytes. Drug Metab Dispos. 2021;49(4):314\u201321. https:\/\/doi.org\/10.1124\/dmd.120.000057.","journal-title":"Drug Metab Dispos."},{"key":"745_CR23","doi-asserted-by":"publisher","first-page":"106590","DOI":"10.1016\/j.vascn.2019.106590","volume":"98","author":"R Khatri","year":"2019","unstructured":"Khatri R, Fallon JK, Rementer RJB, Kulick NT, Lee CR, Smith PC. Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS\/MS in the sandwich cultured human hepatocyte model. J Pharmacol Toxicol Methods. 2019;98:106590. https:\/\/doi.org\/10.1016\/j.vascn.2019.106590.","journal-title":"J Pharmacol Toxicol Methods."},{"issue":"6","key":"745_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1124\/dmd.121.000367","volume":"49","author":"AR Kumar","year":"2020","unstructured":"Kumar AR, Prasad B, Bhatt DK, Mathialagan S, Varma MVS, Unadkat JD. In vivo-to-in vitro extrapolation of transporter-mediated renal clearance: relative expression factor versus relative activity factor approach. Drug Metab Dispos. 2020;49(6):470\u20138. https:\/\/doi.org\/10.1124\/dmd.121.000367.","journal-title":"Drug Metab Dispos."},{"issue":"9","key":"745_CR25","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1124\/dmd.114.058412","volume":"42","author":"A Kunze","year":"2014","unstructured":"Kunze A, Huwyler J, Camenisch G, Poller B. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos. 2014;42(9):1514\u201321. https:\/\/doi.org\/10.1124\/dmd.114.058412.","journal-title":"Drug Metab Dispos."},{"issue":"6","key":"745_CR26","first-page":"637","volume":"27","author":"X Liu","year":"1999","unstructured":"Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KL. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos. 1999;27(6):637\u201344.","journal-title":"Drug Metab Dispos."},{"issue":"4","key":"745_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1046\/j.1365-2125.2003.01881.x","volume":"56","author":"ZE Wilson","year":"2003","unstructured":"Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, et al. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol. 2003;56(4):433\u201340. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01881.x.","journal-title":"Br J Clin Pharmacol."},{"issue":"7","key":"745_CR28","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/a:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093\u20135. https:\/\/doi.org\/10.1023\/a:1018943613122.","journal-title":"Pharm Res."},{"issue":"12","key":"745_CR29","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/0006-2952(94)90255-0","volume":"47","author":"GW Sandker","year":"1994","unstructured":"Sandker GW, Weert B, Olinga P, Wolters H, Slooff MJ, Meijer DK, et al. Characterization of transport in isolated human hepatocytes. A study with the bile acid taurocholic acid, the uncharged ouabain and the organic cations vecuronium and rocuronium. Biochem Pharmacol. 1994;47(12):2193\u2013200. https:\/\/doi.org\/10.1016\/0006-2952(94)90255-0.","journal-title":"Biochem Pharmacol."},{"key":"745_CR30","doi-asserted-by":"publisher","unstructured":"Lu Y, Slizgi JR, Brouwer KR, Claire RL, Freeman KM, Pan M, et al. Hepatocellular disposition and transporter interactions with tolvaptan and metabolites in sandwich-cultured human hepatocytes. Drug Metab Dispos. 2016;44(6). https:\/\/doi.org\/10.1124\/dmd.115.067629.","DOI":"10.1124\/dmd.115.067629"},{"issue":"2","key":"745_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1124\/dmd.120.000204","volume":"49","author":"V Kumar","year":"2021","unstructured":"Kumar V, Yin M, Ishida K, Salphati L, Hop C, Rowbottom C, et al. Prediction of transporter-mediated rosuvastatin hepatic uptake clearance and drug interaction in humans using proteomics-informed REF approach. Drug Metab Dispos. 2021;49(2):159\u201368. https:\/\/doi.org\/10.1124\/dmd.120.000204.","journal-title":"Drug Metab Dispos."},{"issue":"7","key":"745_CR32","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1124\/dmd.113.056309","volume":"42","author":"A Vildhede","year":"2014","unstructured":"Vildhede A, Karlgren M, Svedberg EK, Wisniewski JR, Lai Y, Noren A, et al. Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos. 2014;42(7):1210\u20138. https:\/\/doi.org\/10.1124\/dmd.113.056309.","journal-title":"Drug Metab Dispos."},{"issue":"6","key":"745_CR33","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1177\/1091581820953066","volume":"39","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wilkerson M, Li J, Zhang W, Owens A, Wright S, et al. Assessment of statin interactions with the human NTCP transporter using a novel fluorescence assay. Int J Toxicol. 2020;39(6):518\u201329. https:\/\/doi.org\/10.1177\/1091581820953066.","journal-title":"Int J Toxicol."},{"issue":"2","key":"745_CR34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.molcel.2019.05.006","volume":"75","author":"C Ritchie","year":"2019","unstructured":"Ritchie C, Cordova AF, Hess GT, Bassik MC, Li L. SLC19A1 Is an importer of the immunotransmitter cGAMP. Mol Cell. 2019;75(2):372\u201381 e5. https:\/\/doi.org\/10.1016\/j.molcel.2019.05.006.","journal-title":"Mol Cell."},{"issue":"6","key":"745_CR35","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1021\/acscentsci.1c00440","volume":"7","author":"AF Cordova","year":"2021","unstructured":"Cordova AF, Ritchie C, Bohnert V, Li L. Human SLC46A2 is the dominant cGAMP importer in extracellular cGAMP-sensing macrophages and monocytes. ACS Cent Sci. 2021;7(6):1073\u201388. https:\/\/doi.org\/10.1021\/acscentsci.1c00440.","journal-title":"ACS Cent Sci."},{"issue":"4","key":"745_CR36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.molcel.2020.10.021","volume":"80","author":"LJ Lahey","year":"2020","unstructured":"Lahey LJ, Mardjuki RE, Wen X, Hess GT, Ritchie C, Carozza JA, et al. LRRC8A:C\/E heteromeric channels are ubiquitous transporters of cGAMP. Mol Cell. 2020;80(4):578\u201391 e5. https:\/\/doi.org\/10.1016\/j.molcel.2020.10.021.","journal-title":"Mol Cell."},{"issue":"6","key":"745_CR37","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.clinre.2012.06.006","volume":"36","author":"R Kubitz","year":"2012","unstructured":"Kubitz R, Droge C, Stindt J, Weissenberger K, Haussinger D. The bile salt export pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol. 2012;36(6):536\u201353. https:\/\/doi.org\/10.1016\/j.clinre.2012.06.006.","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"2","key":"745_CR38","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1124\/jpet.105.084830","volume":"314","author":"M Hirano","year":"2005","unstructured":"Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. Bile salt export pump (BSEP\/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005;314(2):876\u201382. https:\/\/doi.org\/10.1124\/jpet.105.084830.","journal-title":"J Pharmacol Exp Ther."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-022-00745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-022-00745-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-022-00745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:28:02Z","timestamp":1669166882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-022-00745-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1208\/s12248-022-00745-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"type":"electronic","value":"1550-7416"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors (except Philip C. Smith and John K. Fallon) are current or former employees of Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA hold common stocks in Takeda Pharmaceutical Company Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"99"}}